Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Kevin Caliendo | UBS | 8 questions · 0% challenging |
| Patrick Donnelly | Citigroup | 7 questions · 0% challenging |
| Mike Cherny | Leerink Partners | 7 questions · 0% challenging |
| Jack Meehan | Operon Research | 7 questions · 0% challenging |
| Erin Wright | Morgan Stanley | 7 questions · 0% challenging |
| Andrew Brackmann | William Blair | 6 questions · 0% challenging |
| David Westenberg | Piper Sandler | 6 questions · 0% challenging |
| Noah Kava | Jefferies | 5 questions · 0% challenging |
| Elizabeth Anderson | Evercore ISI | 5 questions · 0% challenging |
| Mike Ryskin | Bank of America | 5 questions · 20% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| UBS | 1 analyst | 8 questions · 0% challenging |
| Operon Research | 1 analyst | 7 questions · 0% challenging |
| Morgan Stanley | 1 analyst | 7 questions · 0% challenging |
| Leerink Partners | 1 analyst | 7 questions · 0% challenging |
| Citigroup | 1 analyst | 7 questions · 0% challenging |
| Jefferies | 2 analysts | 7 questions · 0% challenging |
| Barclays | 2 analysts | 7 questions · 0% challenging |
| William Blair | 1 analyst | 6 questions · 0% challenging |
Quest posted 9.2% revenue growth with 9% organic acceleration and adjusted EPS of $2.50 (up 15%), with operating margin expanding to 15.4%. FY2026 guidance was raised to $11.78-11.9 billion revenue and $10.63-10.83 EPS on strong Q1 momentum. AD-Detect Alzheimer's testing more than doubled, Fresenius and Corewell contributed to 7% organic volume, and AI-driven automation was enhancing productivity and patient engagement.
Demand | Regulation Policy | Margin | Competitive Dynamics | Revenue Growth | Innovation & R&D | Capex Investment | Product Launch | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 2 |
| 2025Q1 | 4 | 3 | 1 | 2 | 1 | 1 | ||
| 2025Q2 | 6 | 3 | 3 | 1 | 3 | 1 | 1 | 1 |
| 2025Q3 | 5 | 2 | 2 | 2 | 3 | 4 | 3 | 2 |
| 2025Q4 | 7 | 2 | 5 | 2 | 3 | 2 | 2 | 1 |
| 2026Q1 | 5 | 4 | 2 | 3 | 1 | 2 | 3 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 4 | 4 | 6 | 5 | 7 | 5 |
| Regulation Policy | 4 | 3 | 3 | 2 | 2 | 4 |
| Margin | 2 | 1 | 3 | 2 | 5 | 2 |
| Competitive Dynamics | 2 | 2 | 1 | 2 | 2 | 3 |
| Revenue Growth | 2 | 3 | 3 | 3 | 1 | |
| Innovation & R&D | 1 | 1 | 1 | 4 | 2 | 2 |
| Capex Investment | 1 | 1 | 3 | 2 | 3 | |
| Product Launch | 2 | 1 | 1 | 2 | 1 | 1 |
No 8-K events recorded for this window.
Calendar quarter Q1 2026Earnings call Apr 21, 2026
FY2026 Q1 in brief
Quest posted 9.2% revenue growth with 9% organic acceleration and adjusted EPS of $2.50 (up 15%), with operating margin expanding to 15.4%.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +9.16% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Quest Diagnostics (DGX), FY2026 Q1: 9/10. Scores: Quest Diagnostics’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: DGX daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $2.62B | +14.6% | $1.95 | +14.7% | 32.7% | 13.8% | 8.5% | $341M |
| FY2025 Q1 | $2.65B | +12.1% | $1.94 | +12.8% | 32.5% | 13.0% | 8.3% | $197M |
| FY2025 Q2 | $2.76B | +15.2% | $2.47 | +21.1% | 34.2% | 15.9% | 10.2% | $436M |
| FY2025 Q3 | $2.82B | +13.2% | $2.16 | +8.5% | 33.7% | 13.7% | 8.7% | $419M |
| FY2025 Q4 | $2.81B | +7.1% | $2.18 | +11.8% | 32.6% | 13.9% | 8.7% | $307M |
| FY2026 Q1Selected | $2.90B | +9.2% | $2.24 | +15.5% | 32.5% | 13.8% | 8.7% | $164M |
| FY2026 Q2 | $3.04B | +10.2% | $2.84 | +15.0% | 33.7% | 15.1% | 10.5% | $330M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
What DGX and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“Function Health did acquire Getlabs. We think that's a real positive for Function Health.”
Consumer-health partner Function Health acquired mobile phlebotomy firm Getlabs, which Quest views as positive since collected specimens flow to Quest labs.
“we announced a partnership to distribute -- do blood collections for the Guardant colon cancer CRC test”
Quest performs blood collections at its patient service centers for Guardant's Shield colorectal cancer test.
“It was a study between us, Google Health and Fitbit that really highlighted the linkage between biometrics and biomarkers”
Quest, Google Health and Fitbit co-authored a Nature study linking wearable biometrics and lab biomarkers, a partnership signal for Alphabet.
“our AI tool, which is powered by Google Gemini”
Quest's new AI Companion patient tool is powered by Google Gemini, an AI supplier relationship for Alphabet.
“we recently announced a research collaboration with City of Hope, a cancer and research treatment organization to study the use of our Haystack MRD test”
Quest partnered with cancer center City of Hope to study its Haystack MRD test for recurrence monitoring across 14 U.S. sites.
“the majority of this growth coming from our collaborative lab solutions for Corewell Health, a leading health system in Michigan”
Quest's Co-Lab collaboration and planned joint-venture lab with Michigan health system Corewell Health drove double-digit hospital-channel growth.
“In addition to volume from serving thousands of dialysis clinics operated by Fresenius Medical Care nationwide, we also added independent dialysis clinics and other providers as clients of our lab and water purity testing.”
Quest's national lab testing relationship with Fresenius Medical Care's dialysis clinics is a major volume driver in its new end-stage renal disease business.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
DGX Quest Diagnostics | 9 | +9.2% | |
| A Agilent Technologies | 6 | +7.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| ILMN Illumina, Inc. | 8 | +4.8% | |
| IQV IQVIA | 7 | +8.4% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |